Biotech Values

[DewDiligence]

AMGN submits Xgeva sBLA for prevention of PCa bone mets:

http://finance.yahoo.com/news/Amgen-Submits-Application-to-prnews-2107233735.html?x=0&.v=1

This is an sBLA (rather than an ordinary BLA) because Xgeva is already approved for preventing skeletal-related events in patients who have bone mets (#msg-56882220).

The newly sought indication corresponds to the fourth row in the table in #msg-57938233.

An sBLA for preventing bone mets in metastatic breast cancer will be submitted much later, pending data from the phase-3 trial (see fifth row in #msg-57938233).